Mosaic ImmunoEngineering (OTCMKTS:CPMV – Get Free Report) announced its earnings results on Friday. The company reported ($0.02) earnings per share for the quarter, Zacks reports.
Mosaic ImmunoEngineering Price Performance
CPMV opened at $0.06 on Friday. The company has a market capitalization of $441,640.00, a price-to-earnings ratio of -0.68 and a beta of -0.82. The business’s 50-day moving average price is $0.58 and its two-hundred day moving average price is $0.60. Mosaic ImmunoEngineering has a 1 year low of $0.05 and a 1 year high of $1.05.
About Mosaic ImmunoEngineering
Mosaic ImmunoEngineering (OTCMKTS:CPMV) is a development-stage biotechnology company focused on advancing immunotherapies and vaccine candidates through its proprietary nanoparticle platform. The company leverages virus-like particles derived from the cowpea mosaic virus (CPMV) to serve as both antigen carriers and immune stimulators, aiming to enhance the magnitude and durability of immune responses. By engineering these plant-based VLPs to display target antigens or adjuvant properties, Mosaic ImmunoEngineering seeks to create differentiated candidates for oncology indications and infectious disease prevention.
Operating out of the United States, Mosaic ImmunoEngineering is currently in preclinical stages of development.
Featured Stories
- Five stocks we like better than Mosaic ImmunoEngineering
- 3 Unexpected ETFs Crushing the Market This Summer
- Is Best Buy the AI Winner Hiding in the Electronics Aisle?
- Applied Materials Beat Everything but Wall Street’s Expectations for Margins
- Back From Orbit, Intuitive Machines’ Share Price Enters the Buy Zone
Receive News & Ratings for Mosaic ImmunoEngineering Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mosaic ImmunoEngineering and related companies with MarketBeat.com's FREE daily email newsletter.
